Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy

Clinically effective antigen-based immunotherapy must silence antigen-experienced effector T cells (Teff) driving ongoing immune pathology. Using CD4(+) autoimmune Teff cells, we demonstrate that peptide immunotherapy (PIT) is strictly dependent upon sustained T cell expression of the co-inhibitory...

Descripción completa

Detalles Bibliográficos
Autores principales: McPherson, Rhoanne C, Konkel, Joanne E, Prendergast, Catriona T, Thomson, John P, Ottaviano, Raffaele, Leech, Melanie D, Kay, Oliver, Zandee, Stephanie E J, Sweenie, Claire H, Wraith, David C, Meehan, Richard R, Drake, Amanda J, Anderton, Stephen M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2014
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297948/
https://www.ncbi.nlm.nih.gov/pubmed/25546306
http://dx.doi.org/10.7554/eLife.03416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297948/
https://www.ncbi.nlm.nih.gov/pubmed/25546306
http://dx.doi.org/10.7554/eLife.03416

Ejemplares similares